OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

The Thirteen-Minute Infusion: What Sarclisa's Wearable Injector Signals for Cancer Care

The System Behind Access of New Cancer Drugs with Lisa Thompson Smith

Durvalumab With Radiation Shows Promise in Chemotherapy-Ineligible Locally Advanced NSCLC

Lovett Evan Reddick: Honored to Join GSK as Executive Director, Emerging Therapeutic Areas

Tucatinib Plus Trastuzumab Deruxtecan Shows Activity but No Clear Added Benefit in HER2+ Advanced Breast Cancer

Oncology News, Insights, Stories by OncoDaily

ASCO
Breast Oncology

ASCO Updates Breast Cancer Follow-Up Guidelines With Risk-Based Surveillance Approach

RICE Study: Can Immune Checkpoint Inhibitors Be Used Again After Progression?
Immune Oncology

RICE Study: Can Immune Checkpoint Inhibitors Be Used Again After Progression?

Vincent Rajkumar
Science

Vincent Rajkumar: Limited Duration of Lenalidomide Maintenance is Just as Good as Indefinite Therapy

Maximilian Merz: The Future of Ciltacabtagene Autoleucel in Myeloma

Registration Open for ESMO 2026

Bishal Gyawali: Why Downplaying Terms Should Not Be Used to Describe Toxicities in Cancer

The Story Behind One of Radiation Oncology's Most Influential Companies - CancerWorld

Bipartisan Patients First Act Seeks Major Reform of Medicare Physician Payments

Hope for Stomach Cancer and OncoDaily Announce Strategic Media Partnership

Asparaginase Drug Monitoring in Pediatric ALL: The Brazilian Experience - Resonance

Voices
Khatia Otarashvili

Khatia Otarashvili: WHO Fellowship Opportunities for Public Health Specialists and Researchers

Ola Khorshid: The 1st St. Gallen Congress Brings Global Breast Cancer Experts to Egypt

Gevorg Tamamyan: Is This the Route to Europe?

Flavio Rocha Congratulates Pushpa Neppala on Completing Abdominal Organ Transplant Fellowship

Eduard-Alexandru Bonci: Extremely Grateful for the Learning at Candiolo Cancer Institute IRCCS

Kathryn Anderson’s Final Study Reveals How WNT Signaling Shapes Cell Identity and May Inform Cancer Metastasis Research

Asking Company Members Why They Recommend UICC Membership to Other Organizations

FDA Approvals
Subcutaneous Isatuximab Multiple Myeloma

FDA Approved Subcutaneous Isatuximab: Advancing Anti-CD38 Therapy Delivery in Multiple Myeloma

FDA Approves Belzutifan Plus Pembrolizumab for Adjuvant RCC

FDA Approved Decnupaz, the First ADC for Adults With BPDCN

FDA Approves FoundationOne CDx as Companion Diagnostic for TEPMETKO in METex14 NSCLC

FDA approved Atezolizumab for adjuvant treatment of MDR–positive MIBC

FDA Grants Approval for Oral Decitabine/Cedazuridine With Venetoclax in Newly Diagnosed AML

FDA Greenlit New Pancreatic Cancer Drug Daraxonrasib For Expanded Access

OncoDaily 100
100 influential survivors

100 Influential Cancer Survivors on Social Media: 2026 Edition

100 Xfluencers in Prostate Cancer: Key Opinion Leaders to follow on X (Twitter) in 2025

The 100 Most Influential CEOs in Oncology in 2025 (Full List)

The 100 Most Influential People in Oncology in 2025 (Full List)

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025

100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024

Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

Celebrities and Cancer

OncoCalendar

ESSO Hands-on Course on Minimally Invasive Oesophagectomy and Gastrectomy

European Society of Surgical Oncology

15 Oct
Oesophagectomy and Gastrectomy

ESSO - Advanced Course on Pancreatic Cancer Surgery

European Society of Surgical Oncology

22 Oct
Pancreatic Cancer Surgery

ESSO - Advanced Course on Breast Cancer Surgery

22 Oct
Breast Cancer Surgery

ESSO Basics in Liver Surgery Course

European Society of Surgical Oncology

19 Nov
Liver Surgery

3rd Symposium: Artificial Intelligence in Public Health Research

Robert Koch Institute | Centre for Artificial Intelligence in Public Health Research (RKI ZKI-PH)

09 Sep
3rd Symposium: Artificial Intelligence in Public Health Research

Immune-oncology
Tumor Microenvironment: Why It Matters for Cancer Immunotherapy

Tumor Microenvironment: Why It Matters for Cancer Immunotherapy

RICE Study: Can Immune Checkpoint Inhibitors Be Used Again After Progression?

KEYNOTE-C93: Pembrolizumab May Replace Chemotherapy in dMMR Endometrial Cancer

NK-Cell Immunotherapy: The Next Frontier in Cancer Treatment

ChemRNA: A New Generation of Simplified RNA Vaccines for Cancer Immunotherapy

10 Must-Read Posts in Immuno-Oncology This Week

FDA Approves Perioperative Pembrolizumab Plus Enfortumab Vedotin for Muscle-Invasive Bladder Cancer

Gastrointestinal-Oncology
anal cancer

Anal Cancer Survivors Report Lower Physical, Social and Emotional Functioning

PERISCOPE II: Gastrectomy, Cytoreductive Surgery, and HIPEC Do Not Improve Survival in Gastric Cancer With Limited Peritoneal Metastases

Inside the ROBBIN Phase 3 Strategy: Bringing BOT+BAL Into the Neoadjuvant Setting

TOPAZ-1 Post Hoc Analysis: Durvalumab Plus GemCis in Advanced Biliary Tract Cancer

10 Must-Read Posts In GI Oncology This Week

From “Most Promising” to Phase 3: Up to $340M to Advance BOT/BAL in MSS Colon Cancer

Highlights of ESMO GI 2026 in Colorectal Cancer with Davide Ciardiello

Breast-Oncology
Avutometinib

Avutometinib Triplet Shows Feasibility After CDK4/6 Inhibitor Progression in HR+/HER2− Metastatic Breast Cancer

Investigator-Assessed PFS May Be Comparable to BICR in HR+/HER2− Metastatic Breast Cancer Trials

ASCO Updates Breast Cancer Follow-Up Guidelines With Risk-Based Surveillance Approach

Tucatinib Plus Trastuzumab Deruxtecan Shows Activity but No Clear Added Benefit in HER2+ Advanced Breast Cancer

FDA Approves Gedatolisib - Based Therapy for HR+/HER2− Advanced Breast Cancer Without PIK3CA Mutation

SERENA-6: Switching to Camizestrant at ESR1 Mutation Emergence Extends First-Line Benefit in HR+/HER2− Advanced Breast Cancer

Germline Multigene Testing May Identify Higher-Risk Invasive Lobular Breast Cancer

Lung-Oncology
Lung Transplant

Lung Transplant for Lung-Only Stage IV NSCLC: A Bold Idea With Major Caveats

Durvalumab With Radiation Shows Promise in Chemotherapy-Ineligible Locally Advanced NSCLC

Sacituzumab Tirumotecan Plus Pembrolizumab Meets Phase III Endpoint in First-Line PD-L1-Negative Non-Squamous NSCLC

ADC-Related Interstitial Lung Disease: A Class-Relevant Toxicity That Requires Early Recognition

Risvutatug Rezetecan Meets Overall Survival Endpoint in Phase III SCLC Trial in China

Comprehensive Genomic Profiling Delays in Lung Cancer: Biopsy-to-Order Time Remains the Biggest Barrier

Pretreatment SUVmax May Help Identify Which Early-Stage NSCLC Patients Benefit From Consecutive Daily SBRT

Oncology Tech
James Hadfield

James Hadfield: Emerging Technologies Aim to Democratize Ultra-Sensitive MRD Testing

The radiopharmaceutical land grab — and the isotope bottleneck no one's pricing in

The Thirteen-Minute Infusion: What Sarclisa's Wearable Injector Signals for Cancer Care

Kalshi Launches Sportsbook-Style Markets on Drug Trials and FDA Decisions

After TROP2 and HER2, Is B7-H3 the Next Big ADC Target?

KRAS Grows Up: The Breakthroughs and the Reckonings

Chris Boshoff: FDA Approves First Platinum-Free Perioperative Regimen for Muscle-Invasive Bladder Cancer

Hematology
Non-Hodgkin Lymphoma NHL, DLBCL

Non-Hodgkin Lymphoma (NHL): A Practical Biological Map and Integrative Overview

ENDURANCE Trial: 2 Years of Lenalidomide Maintenance Matches Continuous Therapy in Standard-Risk Multiple Myeloma

Peripheral T-Cell Lymphomas (PTCL): Another Evolving Lymphoma Story

Europe Opens the Door to Epcoritamab-R² in 2L Follicular Lymphoma: A New Standard?

FDA Approved Subcutaneous Isatuximab: Advancing Anti-CD38 Therapy Delivery in Multiple Myeloma

What the WHO Global Status Report on Cancer 2026 Means for Hematology

Outpatient Cilta-cel for Multiple Myeloma: Initial Experience in Carefully Selected Patients

Radiotherapy
anal cancer

Life After Anal Cancer: The Hidden Burden of Chemoradiotherapy

Four-Arc Coplanar VMAT Emerges as a Practical Option for Hippocampal-Sparing Whole-Brain Radiotherapy

Unresectable Stage III NSCLC: Precision Redefines Care

A Looming Collapse: Radiation Oncology’s Access Crisis Is No Longer Theoretical 2026

OLIGOPELVIS 2 Shows Acceptable Toxicity With Salvage Nodal Radiotherapy

Early SBRT Before Chemoimmunotherapy Shows Promise in Borderline Resectable and Locally Advanced Pancreatic Cancer

HYPORT Adjuvant Trial Evaluates Quality of Life After Nodal Radiotherapy

OncoDaily TV
Can Research Funding Save More Lives: Dr. Kimberly Sabelko Explains

Can Research Funding Save More Lives: Dr. Kimberly Sabelko Explains

lisa-thompson-smith-reimbursemement

The System Behind Access of New Cancer Drugs with Lisa Thompson Smith

Elas Sharon, Med News Week

Navigating the Intersection of Immunotherapy and Autoimmunity Dr. Elad Sharon

Rodrigo Sánchez-Bayona open doors

What Makes a Great Oncologist? Insights from Dr. Rodrigo Sánchez-Bayona

Daraxonrasib for Pancreatic Cancer: What’s Next?

Daraxonrasib for Pancreatic Cancer: What’s Next?

1000 doctors standing asco alan sandler

Why 1000 Doctors Gave This Cancer Drug A Standing Ovation?

Empowering Oncologists: Are Digital Literacy Tools Critically Important?

Empowering Oncologists: Are Digital Literacy Tools Critically Important?

ASCO

OncoDaily Highlights from ASCO 2026 Chicago, USA

Episode 17: Global Health Dialogues with Princess Dina and Eman Shannan

Episode 17: Global Health Dialogues with Princess Dina and Eman Shannan

Where You Live Shouldn't Dictate Your Cancer Survival: Dr. Benjamin Anderson

Where You Live Shouldn’t Dictate Your Cancer Survival: Dr. Benjamin Anderson

Investing in Cancer Care: Better Health, Stronger Economies: Herb Riband

Investing in Cancer Care: Better Health, Stronger Economies: Herb Riband

Kefah Mokbel

Kefah Mokbel: Can Diet Influence Cancer Risk and Outcomes?

Not To Miss
Artificial Intelligence

3rd Symposium “Artificial Intelligence in Public Health Research”

2026 IBRI Global Forum on Science, Philanthropy, and Investment

15 Posts Not To Miss From Best of ASCO Africa 2026

Top Growing Medical Universities in Africa: 2026 Edition by BIGR

WHO Calls for Urgent Action as New Cancer Cases Are Projected to Nearly Double by 2050

20 Posts Not To Miss From ESMO GI 2026, Part 2

20 Posts Not To Miss From ESMO GI 2026, Part 1

OncoGrants
Global Ovarian Cancer Research Consortium AI Accelerator Grant — OCRA

Global Ovarian Cancer Research Consortium AI Accelerator Grant — OCRA

ACOG Foundation 2026 Request for Grant Proposals

ACOG Foundation 2026 Request for Grant Proposals

Clinical Trial Award — DoD OCRP

Clinical Trial Award — DoD OCRP

Ovarian Cancer Academy – Early-Career Investigator Award — DoD OCRP

Ovarian Cancer Academy – Early-Career Investigator Award — DoD OCRP

Investigator-Initiated Research Award — DoD Ovarian Cancer Research Program

Investigator-Initiated Research Award — DoD Ovarian Cancer Research Program

Kids Beating Cancer — John Voight Memorial Leukemia Research Grant

Kids Beating Cancer — John Voight Memorial Leukemia Research Grant

Oncologist near me
Oncologist Near Me

Oncologist Near Me – Gregory Kalemkerian: Advancing Lung Cancer Care, Research, and Education
Oncologist Near Me

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership
Oncologist Near Me

Oncologist Near Me – Paolo Tarantino: Shaping the Future of Breast Cancer Treatment
Oncologist Near Me

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care
Oncologist Near Me

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine
Oncologist Near Me

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology
Oncologist Near Me

Oncologist Near Me – Bishal Gyawali: Challenging the Status Quo in Global Oncology
Oncologist Near Me

Oncologist Near Me – Yan Leyfman: A Voice for Innovation, Mentorship, and Impact in Oncology
Oncologist Near Me

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research
Oncologist Near Me

Oncologist Near Me – Enrique Soto: A Leader in Geriatric Oncology and Global Cancer Care

Cancer types
Non-Hodgkin Lymphoma NHL, DLBCL

Non-Hodgkin Lymphoma (NHL): A Practical Biological Map and Integrative Overview

Mantle Cell Lymphoma (MCL): Revealing the Biology Beneath the Mantle and Modern Therapeutic Frontiers

Burkitt Lymphoma: Among the Fastest Growing Yet Most Curable Human Cancers

Diffuse Large B-Cell Lymphoma (DLBCL): Molecular Heterogeneity and Progress in Therapy

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Current Perspectives on an Ultra-Rare Malignancy

Richter Transformation (RT): When Chronic Lymphocytic Leukemia Turns Aggressive

Acute Myeloid Leukemia (AML) in 2026: The Current Landscape and Future Perspectives

CancerWorld

Oncologists
Soumita Majumdar

Soumita Majumdar

Oncologists Location Kolkata, India
Thaís Santana

Thaís Santana

Oncologists Location Goiânia, Brazil
Md Imrul Kaes

Md Imrul Kaes

Oncologists Location Enayetpur, Bangladesh
Gabriele Todisco

Gabriele Todisco

Oncologists Location Milan, Italy
Ilaria Colombo

Ilaria Colombo

Oncologists Location Bellinzona, Switzerland
Ting Bao

Ting Bao

Oncologists Location Boston, USA
Joshua Brody

Joshua Brody

Oncologists Location New York, USA
Hagop-Kantarjian

Hagop Kantarjian

Oncologists Location Houston, USA

Oncology Drugs
Sacituzumab Tirumotecan

Sacituzumab Tirumotecan: What Patients Should Know About This Emerging Cancer Treatment

Sacituzumab Tirumotecan: Clinical Development, Mechanism, and Emerging Role in Modern Oncology

Lurbinectedin: What Patients Should Know

Lurbinectedin in Oncology: Mechanism, Clinical Data, Evolving Role, and Future Directions

Bemarituzumab: What Patients with Gastric Cancer Should Know

Bemarituzumab: Uses in Cancer, Side Effects, Dosages, Expectations and More

GSK5764227 (HS-20093): A Novel B7-H3 Targeted Antibody–Drug Conjugate Under Clinical Investigation

OncoDaily Magazine

New Paper Alert
Rodrigo Lastra del Prado

Rodrigo Lastra del Prado: Benefits of Empathetic Oncologist Patient Communication

ICRA trial

The ICRA trial: Paclitaxel Plus Tremelimumab Shows Activity After Platinum and PD-(L)1 Therapy in Metastatic Urothelial Cancer

Screening - OncoDaily

A Unified Framework for Pre-Screening and Screening Tools in Oncology Clinical Trials 2026

Cardiovascular Disease

Prevention And Management Of Cardiovascular Disease In Adults With Cancer: IC-OS And MASCC Clinical Practice Statement

EORTC–ESTRO

Endpoints in Metastases Directed Therapy for Oligometastatic Cancer A Review and Consensus by the EORTC–ESTRO OligoCare Consortium

MONTBLANC Trial

MONTBLANC Trial Recruitment Completed: Triple Immunotherapy in Advanced HCC

OncoDaily Medical Journal

Oncology Nursing

10.69690/ODMJ-011-0626-7610

Major oral hemorrhage after tongue cancer surgery: A case report
Case Reports & Case Series

Lung Cancer

10.69690/ODMJ-001-0626-7958

Evaluation of Intra-Fractional Target Position Variation during Deep Inspiration Breath-Hold (DIBH) Sessions in Lung Stereotactic Body Radiotherapy (SBRT)
Original Research

Hematology

10.69690/ODMJ-001-0526-7344

Analysis of Mortality Factors in the Pediatric Hemato-Oncology Department of the Children's Hospital of Rabat, 2022-2023
Original Research

Radiation Oncology

10.69690/ODMJ-011-0526-7409

An Independent Read-Only Verification and Risk-Management System to Maintain Radiotherapy Safety During Oncology Information System Failure
Case Reports & Case Series

Cancer Care

10.69690/ODMJ-001-0426-7451

Distinct differences in the tumour-resident microbiome between early- and late-onset colorectal cancer
Original Research

Hematology

10.69690/odmj-012-0426-7512

Frailty, infections, and bispecific antibodies in multiple myeloma: redefining supportive care in the era of T-cell redirection
Commentaries

Oncology Nursing

10.69690/ODMJ-002-0426-7359

Barriers and Facilitators of Oral Nutritional Supplement Adherence in Cancer: A Systematic Review
Reviews

Hematology

10.69690/ODMJ-011-0426-7452

Double Dilemma: Managing a Sequential Lymphoma (Case Report)
Case Reports & Case Series